Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Efficacy, and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients

NCT05956509 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05956509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05956509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Efficacy, and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
January 12, 2024
Completion date
June 2, 2024
Enrollment
1 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

upper limb spasticity